Title Fractioned CO2 Laser in the Treatment of Chronic Phase Peyronie's Disease

Last updated: September 10, 2025
Sponsor: Ottawa Hospital Research Institute
Overall Status: Active - Recruiting

Phase

1

Condition

Peyronie's Disease

Treatment

Fractional CO2 laser

Sham (No Treatment)

Clinical Study ID

NCT07177833
20240299-01H
  • Ages > 18
  • Male

Study Summary

Peyronie's Disease (PD) is a fibrosing disorder of the penis where scar tissue (composed of excessive and disorganized collagen) known as a "plaque," forms along the shaft of the penis. This plaque can lead to permanent penile deformity (curvature, narrowing, indentation, hinging), loss of penile length, erectile dysfunction, and pain during intercourse. Research has shown PD to negatively impact the quality of life and cause significant psychosocial distress for many men.

At present, available medical and surgical treatment modalities for PD have limitations. Intralesional collagenase clostridium histolyticum (CCh) is approved for the reduction of penile curvature in PD, however, its use is restricted to the United States market. Other medical therapies including intralesional verapamil and interferon injections have inconsistent and modest effects while, invasive surgical management with plication or grafting can result in erectile dysfunction, penile length shortening, penile sensory changes, and harvest site complications.

Fractional CO2 Laser Therapy is an extra-dermal (applied to the surface of the skin) and non-invasive treatment that involves the use of lasers to destroy and reduce abnormal collagen in scarred tissue. Most recently, it has been used in a pilot clinical trial investigating its use in the management of PD. All men in this study safely experienced reduction in their penile curvature.

This will be a phase 1 clinical trial evaluating the safety and feasibility of using a fractional CO2 laser in the management of chronic phase PD. Enrolled study participants will undergo an initial clinical assessment of their PD which involves penile measurements at flaccid and erect states, a curvature assessment with duplex ultrasound, and will be asked to complete the International Index of Erectile Function Questionnaire (IIEF-5), and Peyronie's Disease Questionnaire (PDQ). They will then undergo 3 laser therapy sessions at 6 week intervals and will have a short and long-term follow-up of 24 and 52 weeks, respectively.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Men 18 or older. For heterosexual men it is required they be in a stablerelationship with a female spouse/partner for at least 3 months and willing to havevaginal intercourse for purposes of properly filling out the validated PDQuestionnaire.

  2. Diagnosis of PD for at least 12 months with evidence of stable disease as determinedby the investigator (i.e. no change in penile curve for at least 6 months andabsence of pain).

  3. Penile curvature of 30º-90º in the dorsal, lateral, or dorsal/lateral plane (must bepossible to delineate the single plane of maximal curvature for evaluation)

  4. Signed informed REB-approved consent agreement; signed authorization form to allowdisclosure of protected information.

  5. Ability to read, complete, and understand the various rating instruments in English.

Exclusion

Exclusion Criteria:

  1. Penile curvature of <30º or >90º

  2. Any conditions affecting the penis such as a chordee in the presence or absence ofhypospadias; thrombosis of the dorsal penile artery; infiltration by a benign ormalignant mass or an infectious agent; ventral curvature from any cause; presence ofan active sexually transmitted disease.

  3. Failure to achieve a sufficient 8/10 erection (after prostaglandin E or Trimixadministration), in the opinion of the investigator, to accurately measure thepenile deformity.

  4. Calcified plaque as evident by appropriate radiographic evaluation, i.e., penileultrasound that would prevent treatment with Fractional CO2 Laser

  5. Isolated hourglass deformity of the penis without curvature

  6. Treatment or plans to undergo treatment for PD, including but not limited to anyprevious surgery, oral/topical agents within 3 months, intralesional medicaltherapies within 3 months, extracorporeal shock wave therapy within 6 months, or useof mechanical devices within 2 weeks before the start of the study

Study Design

Total Participants: 60
Treatment Group(s): 2
Primary Treatment: Fractional CO2 laser
Phase: 1
Study Start date:
October 01, 2025
Estimated Completion Date:
October 01, 2027

Connect with a study center

  • The Ottawa Hospital

    Ottawa 6094817, Ontario 6093943 K1Y4E9
    Canada

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.